633335-81-6

Basic information

• Product Name: Ethanone, 1-(5-broMo-6-fluoro-1H-indazol-1-yl)-
• Synonyms: Ethanone, 1-(5-broMo-6-fluoro-1H-indazol-1-yl)-;1-(5-bromo-6-fluoroindazol-1-yl)ethanone;1-(5-bromo-6-fluoro-1H-indazol-1-yl)ethanone;1-(5-BROMO-6-FLUORO-1H-INDAZOL-1-YL)ETHANONE(WX142566)
• CAS NO: 633335-81-6
• Molecular Formula: C9H6BrFN2O
• Molecular Weight: 257.0591432
• Mol File: 633335-81-6.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethanone, 1-(5-broMo-6-fluoro-1H-indazol-1-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(5-broMo-6-fluoro-1H-indazol-1-yl)-(633335-81-6)
• EPA Substance Registry System: Ethanone, 1-(5-broMo-6-fluoro-1H-indazol-1-yl)-(633335-81-6)

Safety Data

• Hazardous Substances Data: 633335-81-6(Hazardous Substances Data)

Upstream product

• 52723-82-7 4-bromo-5-fluoro-2-methylaniline 
• 108-24-7 acetic anhydride 
• 110-46-3 isopentyl nitrite 
• 367-29-3 3-fluoro-6-methylaniline 
• 366-49-4 5’-fluoro-2’-methylacetanilide 
• 540-80-7 tert.-butylnitrite 
• 633335-80-5 N-(4-bromo-5-fluoro-2-methylphenyl)acetamide 

Downstream Products

• 105391-70-6 5-bromo-6-fluoro-1H-indazole 
• 633327-11-4 6-fluoro-1H-indazole-5-carbonitrile 
• 1126425-15-7 6-fluoro-1H-indazole-5-carbaldehyde 

Relevant articles and documents

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.